Arcutis Biotherapeutics (ARQT) News Today

Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) is under pressure after its third-quarter profit fell short of expectations. A new Phase 3 study and a commercial leadership appointment provide potential longer-term positives, while revenue modestly exceeded estimates.

• Positive Sentiment: Arcutis enrolled the first participant in INTEGUMENT-3, a Phase 3 trial of ZORYVE cream 0.3% for moderate-to-severe atopic dermatitis. The study could support expanding ZORYVE’s use if successful. Phase 3 study announcement
• Positive Sentiment: Third-quarter revenue of $143.92 million slightly topped analysts’ $142.59 million consensus, offering some support amid the earnings miss. Quarterly results and business update
• Neutral Sentiment: Arcutis appointed Rob Lisicki as chief commercial officer, effective November 4. The appointment adds commercial leadership, though the announcement did not specify a new strategy or financial impact. Chief commercial officer appointment
• Neutral Sentiment: Several executives sold shares, including a 40,000-share sale by EVP Masaru Matsuda under a pre-arranged trading plan. The reports say the transactions were connected to tax withholding on equity awards, which may temper concern about the sales. Insider sale report
• Negative Sentiment: Third-quarter EPS was $0.06, missing analysts’ estimates of roughly $0.17–$0.18 and matching the year-ago figure. The earnings shortfall is the clearest near-term negative for investor sentiment despite the revenue beat. Q3 earnings estimate report